Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programsTORONTO, ON / / September 15, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)CSE:RVV(Frankfurt:31R), a lif…